Table 2.
Multivariate log-linear regression model showing independent predictors of mortality rate during the highly active anti-retroviral therapy (HAART) era. As for the univariate analysis, nucleoside analogue (NA) alone-based therapy is not considered HAART, even though these patients received this treatment in the HAART era.
| Variable | Rate ratio¶ | 95% CI | Wald statistics P-value |
|---|---|---|---|
| Demographic information | |||
| Sex | |||
| Female | 1·19 | (1·02–1·38) | 0·028 |
| Male | 1 | ||
| Age at entry to cohort | |||
| > 39 years | 1·03* | (1·02–1·03) | < 0·001 |
| Immunological information | |||
| Nadir CD4 count (if dead then nadir prior to death) | |||
| Missing | 3·64 | (2·66–4·98) | < 0·001 |
| ≤ 14 | 1·93 | (1·62–2·30) | < 0·001 |
| 15–143 | 1·78 | (1·49–2·11) | < 0·001 |
| 144–289 | 1·14 | (0·95–1·36) | 0·162 |
| > 289 | 1 | ||
| Nadir CD19 count | |||
| Missing | 0·93 | (0·32–2·67) | 0·886 |
| < 39 | 1·37 | (1·15–1·63) | < 0·001 |
| 39–76 | 1·06 | (0·88–1·27) | 0·553 |
| 77–130 | 0·87 | (0·72–1·05) | 0·142 |
| > 131 | 1 | ||
| Most recent CD8 (if dead then CD8 pre-death) | |||
| Missing | 2·35 | (0·81–6·80) | 0·114 |
| 595 | 1·92 | (1·63–2·26) | < 0·001 |
| 596–845 | 1·10 | (0·92–1·32) | 0·303 |
| 846–1159 | 0·98 | (0·81–1·18) | 0·833 |
| > 1160 | 1 | ||
| Virological information | |||
| Max VL (if dead then maximum VL pre-death) | |||
| Missing | 1·31 | (1·10–1·56) | 0·002 |
| < 14860 | 0·84 | (0·71–0·99) | 0·034 |
| 14860–82988 | 0·82 | (0·70–0·96) | 0·014 |
| 82989–286177 | 0·85 | (0·73–0·98) | 0·030 |
| > 286177 | 1 | ||
| Anti-retroviral information | |||
| ARV class exposure (if dead then exposure pre-death otherwise at the time of censoring) | |||
| NA only | 0·68 | (0·56–0·82) | < 0·001 |
| PI only | 0·57 | (0·48–0·66) | < 0·001 |
| NNRTI only | 0·45 | (0·39–0·53) | < 0·001 |
| PI + NNRTI | 0·40 | (0·34–0·46) | < 0·001 |
| No ARV hist | 1 |
¶
Adjusted for ethnic origin.
*
Increase in incidence of mortality per year increase in age.